Related Experiment Videos
Is silent ischemia a treatable risk factor in patients with angina pectoris?
1Department of Medicine, University of Florida, Gainesville 32610.
Insights
Silent myocardial ischemia, often undetected, is linked to poor outcomes in coronary artery disease patients. Antianginal drugs effectively reduce silent ischemic episodes, highlighting the need for proactive ischemia management over symptom control.
Area of Science:
- Cardiology
- Ischemic Heart Disease
Background:
- Silent myocardial ischemia is a prevalent condition in patients with coronary artery disease.
- It is characterized by ischemic-type ST-segment shifts without symptoms during stress testing or monitoring.
Purpose of the Study:
- To review the relationship between silent ischemia and adverse outcomes.
- To discuss the role of antianginal agents in managing both symptomatic and silent ischemic episodes.
Main Methods:
- Review of existing literature on silent myocardial ischemia.
- Analysis of data regarding the impact of antianginal agents on ischemic episodes.
Main Results:
- Ambulant ischemia, predominantly silent, shows an independent association with adverse outcomes.
- Antianginal agents can reduce the frequency and duration of silent ischemic episodes when specifically targeted.
Conclusions:
- Current antianginal therapies can effectively manage silent ischemia.
- A strategy focused on detecting and treating silent ischemia, rather than solely managing chest pain, is recommended pending outcome data.
Abstract:
Silent myocardial ischemia is increasingly recognized as a common phenomenon in a variety of populations with coronary artery disease. In patients with angina pectoris, this condition has been recognized during either exercise stress testing or ambulatory monitoring when ischemic-type ST-segment shifts occur without symptoms. Although more information is clearly needed, available data suggest an important independent relation between ambulant ischemia, most of which is silent, and adverse outcome. Other studies show that currently available antianginal agents can prevent or modify symptomatic as well as silent ischemic episodes. Several reports indicate that when these agents are prescribed to control symptomatic ischemic episodes, silent ischemia may continue to occur. Yet, when antianginal drugs are used either alone or in combination in those with recurrent silent ischemia, both the frequency and duration of the silent ischemic episodes are greatly reduced. To date, however, no data are yet available on the impact on outcome of a strategy directed at detecting and treating silent ischemia. Until this information is available, more attention should be focused on identifying and adequately controlling ischemia rather than on simply managing chest pain.